Dr. O'reilly On Areas Of Research In Pancreatic Cancer

Dr. O'Reilly on Areas of Research in Pancreatic Cancer

Dr. O'Reilly Discusses Biomarker Research in Pancreatic Cancer

Dr. O’Reilly on the Potential Role of Veliparib in Pancreatic Cancer

Dr. O’Reilly on Investigational Treatment Approaches in Pancreatic Cancer

Dr. O'Reilly Discusses Advancements in Early Stage Pancreatic Cancer

Dr. O'Reilly on Tarextumab Combinations for Metastatic Pancreatic Cancer

Areas of Future Research Focus in Pancreatic Cancer

Targeted Oncology

Dr. O'Reilly on Immunotherapy in Pancreatic Cancer

Dr. O'Reilly Discusses New Developments in Pancreatic Cancer Care

Targeted Oncology

Dr. Eileen M. O'Reilly on Factors to Consider in Pancreatic Cancer Treatment

Dr. O’Reilly on the Role of Germline Testing in Pancreatic Cancer

Dr. O'Reilly on Resistance to Immunotherapy in Pancreatic Cancer

Dr. O’Reilly on Agents in Development in Advanced Pancreatic Cancer

CancerSmart

Memorial Sloan Kettering Cancer Center

Dr. O’Reilly on the Utility of PARP Inhibitors in Pancreatic Cancer

Pancreatic Cancer | Eileen M O’Reilly, MD

Research To Practice

Dr. O’Reilly on Ongoing Trials With PARP Inhibitors in Pancreatic Cancer

Novel Therapies & New Directions in Pancreas Cancer, 2024 - Eileen O’Reilly, MD

Cancer Patient Lab

Eileen O'Reilly, MD, provides real world evidence to inform treatment of pancreatic cancer patients

Dr. O'Reilly on Nab-Paclitaxel Plus Gemcitabine Vs FOLFIRINOX